Introduction
============

Carbapenems (imipenem and meropenem) have been effective in the treatment of serious infections caused by antibiotic-resistant bacteria, especially multidrug-resistant gram-negative bacilli (MDR-GNB), during the last two or three decades \[[@B1][@B2]\]. However, the number of serious MDR-GNB infections with decreased antimicrobial susceptibility to carbapenems has recently increased \[[@B3][@B4]\]. In this context, doripenem, the latest introduced agent of the carbapenem class, may be a useful alternative treatment option as it shows potent *in vitro* antimicrobial activity against MDR-GNB and clinical effectiveness comparable with other carbapenems \[[@B5][@B6][@B7][@B8][@B9]\]. However, clinicians are usually reluctant to prescribe doripenem, because data regarding doripenem susceptibility are rarely available from widely used automated susceptibility testing panels \[[@B10]\] and the *in vitro* activity of doripenem against clinically significant isolates such as blood isolates has not been reported separately in the context of recent increases in carbapenem resistance, except for a few studies \[[@B11][@B12]\]. One included only blood isolates from bacteremic urinary tract infections, and the other did not include distinct clinical information on bacteremia cases. Therefore, we investigated the doripenem susceptibility of GNB blood isolates from adult patients and correlated it with their clinical data, and compared the *in vitro* antimicrobial activity of doripenem to those of imipenem and other anti-GNB antimicrobial agents in a tertiary care center where doripenem was infrequently prescribed and carbapenem resistance was increasing.

Materials and Methods
=====================

This study was performed at Chung-Ang University Hospital, an 850-bed tertiary care-affiliated hospital in Seoul, Republic of Korea. Between March and December 2012, we identified adult (≥20 years of age) patients whose blood cultures yielded GNB using the computerized database of the study hospital. We reviewed the electronic medical charts of the study patients and collected data on patient demographics, acquisition of infection, underlying diseases/conditions, initial severity of infection, antimicrobial therapy, and mortality.

Bacteremia was classified as community-acquired, healthcare-associated, or hospital-acquired, as described elsewhere \[[@B13]\]. Systemic inflammatory response syndrome (SIRS) criteria were defined as described elsewhere \[[@B14]\]. A site of infection was identified if it was clinically or microbiologically documented. If multiple sites of infection were found in one case, each site was separately recorded. The amount of carbapenem utilization during 2012 at the study hospital was quantified using the total number of defined daily dose (DDD) of the prescribed carbapenems. Carbapenem DDDs were as follows: meropenem (2.0 g), imipenem (2.0 g), and doripenem (1.5 g).

Identification and susceptibility testing of clinical isolates were performed using a Vitek II system (bioMérieux, Hazelwood, MO, USA). During the study period, meropenem susceptibility was not reported for 177 cases (83.5% of 212) due to the process of changing antimicrobial susceptibility panels in the study hospital. Thus, we excluded the reported meropenem susceptibilities of the remaining 35 isolates from the study analysis. Doripenem susceptibility testing was performed separately using the disk diffusion method in accordance with the recommendations of the Clinical and Laboratory Standards Institute (CLSI), because doripenem was not included in the susceptibility panels of the system. Susceptibility was determined based on the diameters of inhibition zones as follows: for Enterobacteriaceae, ≥23 mm (susceptible), 20-22 mm (intermediate resistant), ≤19 mm (resistant); for *Pseudomonas aeruginosa*, ≥19 mm (susceptible), 16-18 mm (intermediate resistant), ≤15 mm (resistant); for *Acinetobacter* spp., ≥18 mm (susceptible), 15-17 mm (intermediate resistant), ≤14 mm (resistant) \[[@B15]\]. Isolates with the result of either \"intermediate resistant\" or \"resistant\" were regarded as \"resistant\". This study was approved by the Institutional Review Board of the Chung-Ang University Hospital \[IRB number, C2012019(714)\].

Results
=======

In the study hospital, the doripenem DDD was 7.3% that of other carbapenems (499 of 6,871 DDDs; 5,418 DDDs for meropenem and 1,453 DDDs for imipenem) in 2012. A total of 212 episodes of GNB bacteremia occurred during the study period. Of these, 8 were polymicrobial cases of GNB and other bacteria, especially gram-positive cocci. Clinical characteristics of the cases are presented in [Table 1](#T1){ref-type="table"}. More than half of the cases were healthcare-associated or hospital-acquired infections (119, 56.1%). Diabetes mellitus was the most common underlying disease (60, 28.3%), followed by solid tumor (55, 25.9%), neurologic disorders (49, 23.1%), and heart failure (24, 11.3%). *Escherichia coli* and *Klebsiella pneumoniae* were most commonly detected (151, 71.2%). Other Enterobacteriaceae and non-fermentative GNB were each found in 30 cases (14.2%). The rate of doripenem resistance (7.5%) was lower than that of imipenem (12.9%) and those of the other anti-GNB antimicrobial agents except amikacin (2.1%). More than a quarter of cases (60, 28.3%) initially presented with severe sepsis or septic shock. The urinary tract was the most common site of infection (96, 45.3%), followed by the lungs (49, 23.1%), central venous catheter (36, 17.0%), abdomen (19, 9.0%), and skin/soft tissue (14, 6.6%).

Doripenem and imipenem susceptibilities are compared in [Table 2](#T2){ref-type="table"}. Almost all imipenem-susceptible isolates were susceptible to doripenem (181/182, 99.5%). One half of the imipenem-resistant isolates (13/26, 50.0%) were also susceptible to doripenem. Doripenem resistance was observed only rarely in the Enterobacteriaceae (2/181, 1.1%). However, for non-fermentative GNB, doripenem resistance was observed in the majority of imipenem-resistant isolates (84.6%, 11/13) and even in a case of imipenem-susceptible *A. baumannii* bacteremia.

[Table 3](#T3){ref-type="table"} presents the rates of antimicrobial resistances of GNB bacteremia isolates according to type of pathogen, site of infection, and type of acquisition. The rate of doripenem resistance was lower than those of the other anti-GNB antimicrobial agents, including imipenem. However, the rate of doripenem resistance was high in cases of *Pseudomonas aeruginosa* bacteremia (40.0%) and *Acintobacter* spp. bacteremia (47.1%). It was also high in cases of pneumonia and hospital-acquired infection (22.4% and 25.9%, respectively). Among hospital-acquired pneumonia cases, the rate of doripenem resistance was 33.3% (4 of 12).

Discussion
==========

Imipenem-susceptible GNB blood isolates were also susceptible to doripenem in almost all cases. Doripenem was more active *in vitro* against GNB blood isolates than other anti-GNB antimicrobial agents, including imipenem. However, in non-fermentative GNB blood isolates and in clinical infections frequently associated with these organisms, especially hospital-acquired pneumonia, the *in vitro* activity of doripenem was limited like that of imipenem.

Imipenem-susceptible GNB blood isolates were also susceptible to doripenem in almost all cases. Although doripenem susceptibility is not routinely reported due to the absence of doripenem in automated susceptibility testing panels, our data suggest that if a GNB blood isolate is susceptible to imipenem, doripenem may be utilized effectively against it. The majority of previous studies also support this suggestion, finding that the *in vitro* activity of doripenem is similar to those of imipenem or meropenem, or sometimes superior to that of imipenem \[[@B5][@B6][@B7][@B8][@B9]\]. A recent study specifically noted that meropenem and imipenem are reliable surrogate markers of doripenem susceptibility according to the surrogate predictive value based on the 2012 CLSI and FDA breakpoints \[[@B10]\]. However, the majority of previous studies included clinical isolates collected before 2010 \[[@B5][@B6][@B7][@B8][@B9][@B10]\]. At that time, doripenem had just been introduced and was not yet widely utilized in clinical practice. This study is not different from previous studies in some ways - doripenem was prescribed only at a rate of 7.4% compared to other carbapenems in this study. Thus, in a clinical setting where doripenem is more frequently prescribed than other carbapenems, doripenem susceptibility may not be predicted based on the susceptibilities of other carbapenems.

Our data showed that doripenem had potent *in vitro* activity against GNB blood isolates compared with other antimicrobial agents, including imipenem. *In vitro* activity of doripenem is reported to be comparable to those of other carbapenems \[[@B5][@B6][@B7][@B8][@B9]\]. In addition, regarding clinical outcomes of complicated urinary tract infection, complicated intra-abdominal infection, nosocomial pneumonia, and bacteremia cases, doripenem shows similar effectiveness compared with other carbapenems \[[@B16][@B17][@B18]\]. These data suggest that doripenem is a valuable antimicrobial treatment option against serious GNB infections. Additionally, considering that the majority of imipenem-resistant Enterobacteriaceae (11/13, 84.6%) were susceptible to doripenem in this study, we suggest that if antimicrobial treatment options are limited against imipenem-resistant Enterobacteriaceae blood isolates, antimicrobial susceptibility tests for doripenem would be helpful to detect additional therapeutic options.

We frequently observed antimicrobial resistance to doripenem among non-fermentative GNB blood isolates in this study. In a previous study that investigated the *in vitro* activity of doripenem in antibiotic-resistant clinical isolates collected from 2001-2002, doripenem was more potent than imipenem or meropenem even against non-fermentative GNB \[[@B19]\]. However, more recent studies of blood GNB isolates reported that doripenem and other carbapenems had similar *in vitro* activity against non-fermentative GNB, similar to the results of our study \[[@B11][@B12]\]. Thus, doripenem should not be considered a treatment option against imipenem-or meropenem-resistant non-fermentative GNB blood isolates, or against hospital-acquired infections or pneumonia in which these GNB isolates are suggested as likely pathogens.

This study has a few important limitations. First, clinical data were retrospectively collected. It might affect the accuracy of the classification of hospital-acquired, healthcare-associated, and community-acquired infection. Second, meropenem susceptibilities could be evaluated only in 35 isolates. Thus, these were not included in the study analysis.

In conclusion, doripenem had more potent *in vitro* activity against GNB blood isolates than other anti-GNB antimicrobial agents, including imipenem, in a clinical setting where doripenem was infrequently utilized. However, its usefulness in clinical practice may be limited by the increasing number of carbapenem-resistant non-fermentative GNB.

**Conflicts of Interest:** This study was sponsored by IL DONG Pharmaceutical Co., Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

###### Clinical characteristics of gram-negative bacilli (GNB) bacteremia cases in a tertiary care center and rates of antimicrobial resistance of the GNB blood isolates

![](ic-47-175-i001)

  Characteristics                                                 No. (%) of bacteremia cases (n = 212)
  --------------------------------------------------------------- ---------------------------------------
  Male sex                                                        96 (45.3)
  Mean age in years (SD)                                          65.9 (15.2)
  Type of acquisition of infection                                
   Community-acquired                                             92/211 (43.6)
   Healthcare-associated                                          92/211 (43.6)
   Hospital-acquired                                              27/211 (12.8)
  Underlying disease or condition                                 
   Diabetes mellitus                                              60 (28.3)
   Solid tumor                                                    55 (25.9)
   Neurologic disorder                                            49 (23.1)
   Heart failure                                                  24 (11.3)
   Hematologic malignancy                                         16 (7.5)
   Hemodialysis                                                   16 (7.5)
   Chronic obstructive pulmonary disease                          12 (5.7)
   Liver cirrhosis                                                9 (4.2)
   Immunosuppressant use within a month                           49 (23.1)
  Pathogen                                                        
   *Escherichia coli*                                             112 (52.8)
   *Klebsiella pneumonia*                                         39 (18.4)
   *Enterobacter* spp.                                            15 (7.1)
   *Citrobacter freundii*                                         5 (2.4)
   *Serratia marcescens*                                          4 (1.9)
   *Morganella morganii*                                          3 (1.4)
   *Proteus mirabilis*                                            3 (1.4)
   *Psuedomonas aeruginosa*                                       10 (4.7)
   *Acinetobacter* spp.                                           17 (8.0)
   *Stenotrophomonas maltophilia*                                 3 (1.4)
   *Aeromonas hydrophila*                                         1 (0.5)
  Resistance to antimicrobial agent                               
   Ciprofloxacin                                                  67/211 (31.8)
   Ceftriaxone                                                    62/209 (29.7)
   Aztreonam                                                      57/209 (27.3)
   Amikacin                                                       4/194 (2.1)
   Gentamicin                                                     50/209 (23.9)
   Ceftazidime                                                    47/210 (22.4)
   Cefepime                                                       37/209 (17.7)
   Piperacillin-tazobactam                                        27/184 (14.7)
   Imipenem                                                       26/209 (12.4)
   Doripenem                                                      16 (7.5)
   Colistin                                                       3/31 (9.7)
  Initial severity of bacteremia                                  
   No sepsis                                                      52/211 (24.6)
   Sepsis                                                         99/211 (46.9)
   Severe sepsis                                                  12/211 (5.7)
   Septic shock                                                   48/211 (22.7)
  Site of infection                                               
   Urinary tract                                                  96 (45.3)
   Lungs                                                          49 (23.1)
   Central venous catheter                                        36 (17.0)
   Abdomen                                                        19 (9.0)
   Skin and soft tissue                                           14 (6.6)
   Bone and joint                                                 4 (1.9)
   Central nervous system                                         4 (1.9)
  Appropriate antimicrobial therapy within 2 days of bacteremia   171 (80.7)
  Length of hospital admission, mean days (SD)                    31.8 (50.2)
  In-hospital mortality                                           40/210 (19.0)
  28-day mortality                                                35/210 (16.7)

SD, standard deviation.

###### Doripenem and imipenem susceptibilities of 208 GNB blood isolates (after the exclusion of *Aeromonas hydrophila* and *Stenotrophomonas maltophilia*)
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  Number of isolates         Susceptible to doripenem   Resistant to doripenem
  -------------------------- -------------------------- ------------------------
  All GNB                                               
   Susceptible to imipenem   181                        1
   Resistant to imipenem     13                         13
  *Enterobacteriaceae*                                  
   Susceptible to imipenem   168                        0
   Resistant to imipenem     11                         2
  Non-fermentative GNB                                  
   Susceptible to imipenem   13                         1
   Resistant to imipenem     2                          11

GNB, gram-negative bacilli.

###### Antimicrobial resistances of anti-gram negative bacilli (GNB) antimicrobial agents according to type of pathogen, site of infection, and type of acquisition among GNB blood isolates in a tertiary care center
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  Characteristics             No. (%) of antimicrobial resistant organisms                                                                                                                                                            
  --------------------------- ---------------------------------------------- ------------ --------------- --------------- ------------- --------------- --------------- --------------- --------------- -------------- -------------- --------------
  Type of pathogen                                                                                                                                                                                                                    
   *Escherichia coli*         74/112 (66.1)                                  0/112        16/112 (14.3)   39/112 (34.8)   0/3           14/112 (12.5)   26/112 (23.2)   16/112 (14.3)   16/112 (14.3)   5/96 (5.2)     2/112 (1.8)    0/112
   *Klebsiella pneumoniae*    39/39 (100)                                    0/39         8/39 (20.5)     10/39 (25.6)    0/1           8/39 (20.5)     5/39 (12.8)     8/39 (20.5)     8/39 (20.5)     2/31 (6.5)     2/39 (5.1)     2/39 (5.1)
   *Enterobacter*spp.         15/15 (100)                                    1/15 (6.7)   5/15 (33.3)     1/15 (6.7)      0/3           1/15 (6.7)      2/15 (13.3)     5/15 (33.3)     5/15 (33.3)     2/15 (13.3)    4/15 (26.7)    0/15
   *Citrobacter freundii*     5/5 (100)                                      0/5          4/5 (80.0)      1/5 (20.0)      ND            0/5             0/5             4/5 (80.0)      4/5 (80.0)      4/5 (80.0)     0/5            0/5
   *Serratia marcescens*      4/4 (100)                                      2/4 (50.0)   2/4 (50.0)      2/4 (50.0)      2/2 (100)     0/4             2/4 (50.0)      2/4 (50.0)      0/4             0/4            0/4            0/4
   *Morganella morgannii*     3/3 (100)                                      1/3 (33.3)   1/3 (33.3)      1/3 (33.3)      ND            1/3 (33.3)      0/3             1/3 (33.3)      1/3 (33.3)      1/3 (33.3)     3/3 (100)      0/3
   *Proteus mirabilis*        1/3 (33.3)                                     0/3          1/3 (33.3)      1/3 (33.3)      ND            1/3 (33.3)      1/3 (33.3)      1/3 (33.3)      1/3 (33.3)      0/3            2/3 (66.7)     0/3
   *Pseudomonas aeruginosa*   10/10 (100)                                    0/10         3/10 (30.0)     3/10 (30.0)     0/9           2/10 (20.0)     6/9 (66.7)      10/10 (100.0)   2/10 (20.0)     3/10 (30.0)    5/10 (50.0)    4/10 (40.0)
   *Acinetobacter* spp.       12/16 (75.0)                                   0/2          16/16 (100)     9/17 (52.9)     12/12 (100)   10/17 (58.8)    7/17 (41.2)     15/17 (88.2)    10/17 (58.8)    9/15 (60.0)    8/17 (47.1)    8/17 (47.1)
  Site of infection                                                                                                                                                                                                                   
   Lung                       43/48 (89.6)                                   2/36 (5.6)   30/48 (62.5)    23/48 (47.9)    0/15          18/48 (37.5)    21/48 (43.8)    32/48 (66.7)    25/48 (52.1)    16/48 (33.3)   16/49 (32.7)   11/49 (22.4)
   Urinary tract              68/94 (72.3)                                   3/92 (3.3)   28/96 (29.2)    28/95 (29.5)    1/8 (12.5)    18/95 (18.9)    25/95 (26.3)    28/95 (29.5)    23/95 (24.2)    11/83 (13.3)   10/96 (10.4)   4/96 (4.2)
   Abdomen                    15/19 (78.9)                                   0/17         4/18 (22.2)     10/19 (52.6)    0/3           4/19 (21.1)     5/19 (26.3)     5/19 (26.3)     4/19 (21.1)     3/18 (16.7)    4/19 (21.1)    2/19 (10.5)
   Central catheter           30/34 (88.2)                                   2/28 (7.1)   17/33 (51.5)    15/36 (41.7)    0/10          11/34 (41.2)    14/34 (41.2)    21/34 (61.8)    13/35 (37.1)    7/28 (25.0)    8/34 (23.5)    5/36 (13.9)
  Type of acquisition                                                                                                                                                                                                                 
   Healthcare-associated      73/90 (81.1)                                   2/82 (2.4)   29/89 (32.6)    34/92 (37.0)    3/16 (18.8)   18/90 (20.0)    22/89 (24.7)    34/90 (37.8)    24/91 (26.4)    13/76 (17.1)   15/90 (16.7)   7/92 (7.6)
   Hospital-acquired          22/25 (88.0)                                   2/22 (9.1)   20/27 (74.1)    16/26 (61.5)    0/8           14/26 (53.8)    12/27 (44.4)    19/26 (73.1)    17/26 (65.4)    10/25 (40.0)   10/27 (37.0)   7/27 (25.9)

AMP, ampicillin; AMK, amikacin; ATM, aztreonam; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; GEN, gentamicin; CRO, ceftriaxone; CAZ, ceftazidime; TZP, piperacillin-tazobactam; IPM, imipenem; DPM, doripenem; ND, not determined.
